200 related articles for article (PubMed ID: 17719232)
1. Immunomodulation against leukemias and lymphomas: a realistic future treatment?
Mittal S; Marshall NA; Barker RN; Vickers MA
Crit Rev Oncol Hematol; 2008 Feb; 65(2):101-8. PubMed ID: 17719232
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy of hematological malignancies using dendritic cells.
Van de Velde AL; Berneman ZN; Van Tendeloo VF
Bull Cancer; 2008 Mar; 95(3):320-6. PubMed ID: 18390412
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapeutic peptide vaccination with leukemia-associated antigens.
Rusakiewicz S; Molldrem JJ
Curr Opin Immunol; 2006 Oct; 18(5):599-604. PubMed ID: 16870418
[TBL] [Abstract][Full Text] [Related]
4. [Monoclonal antibodies for lymphomas and leukemias in 2005].
Peffault de Latour R; Robin M; Bay JO
Bull Cancer; 2006 Jan; 93(1):107-18. PubMed ID: 16455513
[TBL] [Abstract][Full Text] [Related]
5. Advances in specific immunotherapy for prostate cancer.
Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapeutics in development for prostate cancer.
Harzstark AL; Small EJ
Oncologist; 2009 Apr; 14(4):391-8. PubMed ID: 19342474
[TBL] [Abstract][Full Text] [Related]
7. Active and passive immunotherapy for lymphoma: proving principles and improving results.
Brody J; Kohrt H; Marabelle A; Levy R
J Clin Oncol; 2011 May; 29(14):1864-75. PubMed ID: 21482977
[TBL] [Abstract][Full Text] [Related]
8. Immune surveillance and immunotherapy: lessons from carbohydrate mimotopes.
Pashov A; Monzavi-Karbassi B; Kieber-Emmons T
Vaccine; 2009 May; 27(25-26):3405-15. PubMed ID: 19200843
[TBL] [Abstract][Full Text] [Related]
9. Peptide vaccines for patients with acute myeloid leukemia.
Schmitt M; Casalegno-Garduño R; Xu X; Schmitt A
Expert Rev Vaccines; 2009 Oct; 8(10):1415-25. PubMed ID: 19803762
[TBL] [Abstract][Full Text] [Related]
10. [New era of tumor immunotherapy].
Yoshitake Y; Nakatsura T; Nishimura Y
Nihon Rinsho; 2005 Apr; 63 Suppl 4():46-55. PubMed ID: 15861634
[No Abstract] [Full Text] [Related]
11. New frontiers in cell-based immunotherapy of cancer.
D'Elios MM; Del Prete G; Amedei A
Expert Opin Ther Pat; 2009 May; 19(5):623-41. PubMed ID: 19441938
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond.
Zhou Y; Zhang L; Romaguera J; Delasalle K; Han X; Du X; Kwak L; Yi Q; Wang M
Am J Hematol; 2008 Feb; 83(2):144-9. PubMed ID: 17722077
[TBL] [Abstract][Full Text] [Related]
13. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
Horton HM; Bernett MJ; Pong E; Peipp M; Karki S; Chu SY; Richards JO; Vostiar I; Joyce PF; Repp R; Desjarlais JR; Zhukovsky EA
Cancer Res; 2008 Oct; 68(19):8049-57. PubMed ID: 18829563
[TBL] [Abstract][Full Text] [Related]
14. Personalized immunotherapy for the treatment of non-Hodgkin lymphoma: a promising approach.
Vose J
Clin Adv Hematol Oncol; 2005 Dec; 3(12):923-32. PubMed ID: 16555434
[TBL] [Abstract][Full Text] [Related]
15. Hybridoma monoclonal antibody treatment of T-cell lymphomas: clinical experience and nursing management.
DiJulio JE; Bedigian JS
Oncol Nurs Forum; 1983; 10(2):22-27. PubMed ID: 6346276
[No Abstract] [Full Text] [Related]
16. Vaccine immunotherapy in breast cancer treatment: promising, but still early.
Curigliano G; Spitaleri G; Dettori M; Locatelli M; Scarano E; Goldhirsch A
Expert Rev Anticancer Ther; 2007 Sep; 7(9):1225-41. PubMed ID: 17892423
[TBL] [Abstract][Full Text] [Related]
17. [Immunotherapy for cancer--modern immunologic strategies in oncology].
Halama N; Zoernig I; Jäger D
Dtsch Med Wochenschr; 2008 Oct; 133(41):2105-8. PubMed ID: 18985564
[TBL] [Abstract][Full Text] [Related]
18. Randomized clinical studies of anti-tumor vaccination: state of the art in 2008.
Fournier P; Schirrmacher V
Expert Rev Vaccines; 2009 Jan; 8(1):51-66. PubMed ID: 19093773
[TBL] [Abstract][Full Text] [Related]
19. Future directions for immunotherapeutic intervention against sarcomas.
Maki RG
Curr Opin Oncol; 2006 Jul; 18(4):363-8. PubMed ID: 16721132
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]